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ABSTRACT
Cisplatin has been widely employed as a cornerstone chemotherapy treatment 
for a wide spectrum of solid neoplasms; increasing tumor responsiveness to cisplatin 
has been a topic of interest for the past 30 years. Strong evidence has indicated that 
mitochondrial fission participates in the regulation of apoptosis in many diseases; 
however, whether mitochondrial fission regulates cisplatin sensitivity remains poorly 
understood. Here, we show that MFF mediated mitochondrial fission and apoptosis 
in tongue squamous cell carcinoma (TSCC) cells after cisplatin treatment and that 
miR-593-5p was downregulated in this process. miR-593-5p attenuated mitochondrial 
fission and cisplatin sensitivity by targeting the 3’ untranslated region sequence 
of MFF and inhibiting its translation. In exploring the underlying mechanism of 
miR-593-5p downregulation, we observed that BRCA1 transactivated miR-593-5p 
expression and attenuated cisplatin sensitivity in vitro. The BRCA1-miR-593-5p-
MFF axis also affected cisplatin sensitivity in vivo. Importantly, in a retrospective 
analysis of multiple centers, we further found that the BRCA1-miR-593-5p-MFF axis 
was significantly associated with cisplatin sensitivity and the survival of patients 
with TSCC. Together, our data reveal a model for mitochondrial fission regulation at 
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INTRODUCTION
Cisplatin was first approved by the Food and 
Drug Administration (FDA) in 1978 for the treatment 
of testicular and bladder cancer and has been largely 
employed as a cornerstone treatment in the fight against 
a wide spectrum of solid neoplasms, including (but 
not limited to) head and neck, colorectal, ovarian and 
lung cancers [1]. Cisplatin exerts anticancer effects via 
multiple mechanisms; however, its most prominent (and 
best understood) mode of action involves the generation 
of DNA lesions followed by the activation of the DNA 
damage response and the induction of mitochondrial 
apoptosis [1]. Although cisplatin often leads to initial 
therapeutic success, chemoresistance frequently develops 
and leads to therapeutic failure. The initial patient 
responsiveness to platinum-based therapies in oral 
squamous cell carcinoma (OSCC) is 80.6% [2]; however, 
more than 70% of patients eventually relapse because 
their tumors become resistant [3]. Intense research has 
investigated this phenomenon over the past 30 years, and 
several mechanisms have been described to be associated 
with the cisplatin-resistant phenotype of tumor cells, 
including decreased cellular drug accumulation, increased 
levels of glutathione, increased levels of DNA repair 
and increased anti-apoptotic activity [4]. Unfortunately, 
no substantive progress has been made in overcoming 
cisplatin resistance in a clinical setting due to the 
numerous resistance mechanisms that cancer cells have. 
Searching for other mechanisms through which cisplatin 
can exert its apoptotic effects may be the most practical 
avenue for achieving optimal effectiveness for this drug 
in a clinical setting.
Mitochondria have an important role in the 
initiation of apoptosis [5, 6]. In the intrinsic pathway, it 
is generally accepted that mitochondrial outer membrane 
permeabilization (MOMP), which leads to the release 
of pro-apoptotic proteins from the mitochondrial 
intermembrane space (IMS), is the most crucial event 
driving initiator caspase activation and apoptosis. 
However, recent evidence has revealed that certain cell 
types survive MOMP [7, 8]. For example, MOMP could 
be incomplete when some mitochondria fail to undergo 
MOMP following an apoptotic stimulus. Therefore, 
other mitochondrial activities may stimulate the intrinsic 
pathway. Interestingly, recent studies have revealed that 
an abnormal mitochondrial dynamic participates in the 
regulation of apoptosis [9]; this dynamic has been linked 
to a variety of diseases, such as skeletal muscle disorders 
[10, 11], Charcot-Marie-Tooth type 2A peripheral 
neuropathy [12], neurodegeneration [13], acute kidney 
injury [14] and myocardial infarction [15, 16]. Although 
the relationship between MOMP and mitochondrial 
fission during apoptosis in mammalian cells is unclear 
[17], mitochondrial fission appears to occur early in the 
apoptotic pathway or prior to MOMP [18] and can even 
be dissociated from MOMP [19]. Limited studies have 
shown that cisplatin can induce apoptosis in Hela cells 
[20] and ovarian cancer cells [21] through mitochondrial 
fission; nevertheless, no studies have indicated whether 
mitochondrial fission can predict cisplatin sensitivity in a 
clinical setting. In addition, whether mitochondrial fission 
participates in the cisplatin sensitivity of tongue squamous 
cell carcinoma (TSCC) should also be investigated.
DRP1 is a prominent dynamin-related GTPase in 
mammals that induces mitochondrial fission by generating 
the mechanical force that constricts (mechanistically 
pinches) mitochondria [22]. Multiple integral outer-
membrane proteins (including FIS1, MID49/51 and MFF) 
work as DRP1 receptors to recruit DRP1 to mitochondria. 
However, there are conflicting results regarding whether 
inhibiting DRP1 enhances spontaneous apoptosis in 
vitro and in vivo in several cancer types, including colon, 
breast, lung and cervical cancers [23]. Additionally, in 
a previous study, no significant difference was found in 
cumulative survival between patients with high and low 
DRP1 levels in lung adenocarcinomas [24]. Consequently, 
the data suggest that DRP1 executes mitochondrial fission 
and apoptosis in a manner that is co-regulated with its 
pivotal receptor. However, the role of FIS1 and MID49/51 
as outer-membrane proteins (tethers for DRP1) has 
recently been challenged [25, 26]. FIS1 overexpression 
affects neither mitochondria-associated DRP1 nor 
mitochondrial fission [27], whereas MiD49 recruits DRP1 
to the mitochondrial outer membranes and promotes 
mitochondrial fusion rather than fission in vertebrates [28]. 
By contrast, other studies have clearly demonstrated that 
MFF penetrates into the mitochondrial outer membrane 
prior to DRP1 recruitment [29, 30], and DRP1 and MFF 
co-localization structures induce mitochondrial fission 
[31, 32]. However, no studies have indicated whether 
MFF affects cisplatin sensitivity through mitochondrial 
fission. In this study, we focused on MFF-dependent 
mitochondrial fission and revealed a novel mechanism of 
cisplatin sensitivity.
MiRNAs have been implicated in the regulation of 
numerous cellular processes. Some miRNAs have been 
found to regulate cisplatin sensitivity in cancer cells [33]. 
However, it is unknown whether miRNAs could regulate 
cisplatin sensitivity through the mitochondrial fission 
pathway. Interestingly, miRNAs have been reported to 
regulate mitochondrial fission by targeting DRP1 and FIS1 
in mouse cardiomyocytes. Therefore, the role of miRNA 
in cancer cell mitochondrial fission requires further 
investigation.
The present study revealed that MFF regulates 
the transcriptional and post-transcriptional levels; we also reveal a new pathway for 
BRCA1 in determining cisplatin sensitivity through the mitochondrial fission program.
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mitochondrial fission and cisplatin sensitivity in TSCC 
cells. miR-593-5p represses MFF expression by targeting 
the MFF mRNA 3’-UTR. BRCA1 is generally thought to 
regulate cisplatin sensitivity through DNA damage repair; 
however, our in vivo and in vitro experiments showed that 
BRCA1 transactivates miR-593-5p expression and inhibits 
MFF expression through transcriptionally targeting miR-
593-5p, consequently regulating mitochondrial fission 
and cisplatin sensitivity. Our results reveal a model 
for the BRCA1-miR-593-5p–MFF axis in mediating 
mitochondrial fission in cancer cells. More importantly, 
the BRCA1-miR-593-5p–MFF axis is related to 
cisplatin sensitivity and the survival of TSCC patients; 
this discovery may provide novel regulatory factors for 
enhancing cisplatin sensitivity in a clinical setting.
RESULTS
MFF regulates mitochondrial fission and cisplatin 
sensitivity
Cisplatin can induce apoptosis by initiating a 
mitochondrial fission pathway [20,21]. However, the 
underlying mechanism of this effect remains elusive. 
To study the mechanism through which mitochondrial 
fission regulates cisplatin sensitivity in TSCC, we first 
measured morphological changes in TSCC mitochondria 
after cisplatin stimulation(Supplementary Figure S1). We 
observed that mitochondrial fission increased in TSCC 
cells (Supplementary Figure S1B) and that increased 
levels of cytochrome c(CYTO c) were released from 
the intermembrane space of the mitochondria to the 
cytosol (Supplementary Figure S1C) after cisplatin 
treatment. These results indicate that mitochondrial fission 
participates in the apoptosis of TSCC cells after cisplatin 
treatment.
Growing evidence has demonstrated that MFF 
primarily penetrates the mitochondrial outer membrane 
and recruits DRP1 to initiate mitochondrial fission 
and cell apoptosis [29-32]; however, little is known 
regarding the relationship between MFF and cisplatin 
sensitivity. Therefore, we tested whether cisplatin affects 
mitochondrial fission and apoptosis in TSCC cells via 
MFF-dependent machinery.
Cisplatin induced mitochondrial fission with 
elevated MFF protein levels (Figure 1A), but not 
elevated mRNA levels (Supplementary Figure S2A). 
Immunofluorescence microscopy revealed that MFF 
exhibited punctate localization in mitochondria and that 
mitochondria fragmentation occurred upon cisplatin 
treatment of TSCC cells (Supplementary Figure S2B). 
MFF knockdown attenuated the MFF protein upregulation 
(Supplementary Figure S2C) and partially inhibited the 
release of cytochrome c in the intermembrane space 
of mitochondria (Figure 1B) of cisplatin-treated cells. 
Cisplatin induced an alteration in the expression of 
FIS1, DRP1, MFN1, MFN2 and optic atrophy type I 
(OPA1); this alteration was not affected by MFF siRNA 
(Supplementary Figure S2C). Consequently, mitochondrial 
fission (Figure 1C) and the apoptosis of TSCC cells 
(Figure 1D-F) were attenuated by MFF siRNA. By 
contrast, enforced MFF expression led to mitochondrial 
fission and apoptosis (Figure 1G-K). These data suggest 
that MFF regulates mitochondrial fission and cisplatin 
sensitivity in TSCC cells.
miR-593-5p regulates mitochondrial fission and 
cisplatin sensitivity through MFF
To elucidate the molecular mechanisms by which 
MFF protein levels, but not mRNA levels, are upregulated, 
we tested whether miRNAs control MFF expression. We 
analyzed potential targets using a bioinformatics program 
(http://regrna2.mbc.nctu.edu.tw). We found that the 
3’untranslated region (3’UTRs) of MFF had binding sites 
for miR-593-5p (Figure 2A). We first found that miR-593-
5p was downregulated after cisplatin exposure in Cal-27 
cells (Figure 2B). The enforced expression of miR-593-5p 
increased miR-593-5p levels (Supplementary Figure S3A) 
and attenuated the increase in MFF protein levels after 
cisplatin exposure (Figure 2C). By contrast, MFF mRNA 
levels were not altered by miR-593-5p under cisplatin 
conditions (Supplementary Figure S3B). DRP1 and FIS1 
protein levels were also unchanged (Supplementary 
Figure S3C). The knockdown of endogenous miR-593-5p 
resulted in elevated MFF levels (Figure 2D). To determine 
whether MFF is a direct target of miR-593-5p, we tested 
the effect of miR-593-5p on MFF translation. The 
introduction of mutations of MFF-3’UTRs that disrupt 
base pairing between miR-593-5p and MFF rescued 
luciferase expression (Figure 2E) and MFF protein 
expression (Figure 2F). Together, these results suggest that 
miR-593-5p directly targets MFF-3’UTRs. 
Then, we tested whether MFF is a downstream target 
of miR-593-5p during the regulation of mitochondrial 
fission and cisplatin sensitivity. The enforced expression 
of miR-593-5p inhibited mitochondrial fission (Figure 
3A) and apoptosis (Figure 3B-D) after cisplatin exposure 
in Cal-27 cells. However, this inhibitory effect was 
significantly abolished when Cal-27 cells were transfected 
with miR-593-5p mimics along with pcDNA3.1 plasmid 
cloned with MFF expression cassette containing mutant 
3’UTR (MFF-mut-3’UTR) at miR-593-5p response 
element (Figure 3E, Supplementary Figure S3D). Target 
protector technology [34], which disrupts the interaction 
between miRNA-mRNA pairs, has been used to identify 
the specific recognition sequence of a miRNA to a 
target region. We employed an MFF target protector 
(TP) and found that the inhibitory effect of miR-593-
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Figure 1: MFF regulates mitochondrial fission and apoptosis in TSCC cells after cisplatin treatment. A, Cisplatin 
induces mitochondrial fission with elevated MFF protein levels in Cal-27 and Scc-9 cells. Upper panel: MFF levels were analyzed via 
immunoblotting after cisplatin treatment. Lower panel: the quantification of cells with mitochondrial fission. #P < 0.05 versus no cisplatin 
treatment; *P < 0.01 versus no cisplatin treatment; **P < 0.001 versus no cisplatin treatment. B, Cytochrome c (CYTO c) distribution 
in mitochondria-enriched heavy membranes (HM) or the cytosol as detected via immunoblotting. C, D, E and F, Knockdown of MFF 
attenuated cisplatin-induced mitochondrial fission and apoptosis in Cal-27 and Scc-9 cells. Mitochondrial fission was detected via staining 
with MitoTracker Red. Scale bar equals 3 µm. Cell apoptosis was detected using TUNEL, flow cytometry, and caspase-3/7 activity assays. 
*P < 0.01 versus cisplatin alone; **P< 0.001 versus cisplatin alone. G, Cal-27 and Scc-9 cells transiently transfected with MFF expressing 
plasmids for 24 h were analyzed for MFF levels via immunoblotting. H, I, J and K, Mitochondrial fission and apoptosis were detected via 
staining with MitoTracker Red, flow cytometry, TUNEL, and caspase-3/7 activity assays. *P < 0.01 versus no cisplatin treatment; **P < 
0.001 versus no cisplatin treatment.
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5p on mitochondrial fission and apoptosis was reduced 
in the presence of the MFF target protector (Figure 3F, 
Supplementary Figure S3E). Furthermore, we attempted 
to determine whether the regulation of miR-593-5p on 
MFF was cell type-specific and observed that miR-593-5p 
levels were also decreased in Scc-9 cells after cisplatin 
exposure (Supplementary Figure S4A). Exogenous miR-
593-5p expression concomitantly increased miR-593-
5p levels(Supplementary Figure S4B) and attenuated 
MFF protein levels(Supplementary Figure S4C) without 
affecting MFF mRNA levels(Supplementary Figure S4D). 
Meanwhile, mitochondrial fission and cell apoptosis were 
also attenuated by exogenous miR-593-5p expression in 
Scc-9 cells(Supplementary Figure S4E and S4F). These 
data suggest that miR-593-5p functionally controls 
mitochondrial fission and cisplatin sensitivity through its 
MFF downstream target in TSCC cells. 
BRCA1 transactivates miR-593-5p and influences 
mitochondrial fission and cisplatin sensitivity 
through miR-593-5p and MFF
We investigated how miR-593-5p expression 
could be downregulated under cisplatin stress. miRNA 
expression has been reported to be regulated at the 
transcriptional level under physiological and pathological 
conditions [35,36]. We analyzed the 5-kb region upstream 
of miR-593-5p and observed that it contains ten possible 
binding sites (BS) for the transcription factor BRCA1 
(jaspar.genereg.net; Supplementary Figure S5A). This 
result led us to investigate whether BRCA1 is involved in 
the regulation of miR-593-5p expression.
First, we observed that BRCA1 was downregulated 
under cisplatin stress in Cal-27 cells (Figure 4A). 
BRCA1 siRNA (Supplementary Figure S5B) or the 
Figure 2: miR-593-5p targets the 3’UTR of MFF. A, Analysis of miR-593-5p targeting sites in MFF 3’UTR via regrna2 (http://
regrna2.mbc.nctu.edu.tw) and the construction of MFF 3’UTR mutants(mut). B, qRT-PCR was performed to analyze miR-593-5p levels 
under cisplatin treatment in Cal-27 cells. *P < 0.01 versus no cisplatin treatment; **P < 0.001 versus no cisplatin treatment. C, Forced 
expression of miR-593-5p attenuated the cisplatin-induced increase in MFF protein levels. Cal-27 cells were transfected with miR-593-5p 
mimics or miR-593-5p control (miR-con). After 24h of transfection, the cells were exposed to cisplatin and harvested 24 h after treatment 
for MFF analysis via immunoblotting. D, Knockdown of miR-593-5p upregulated MFF levels. Cal-27 cells were transfected with miR-593-
5p inhibitors or negative control(inhibitors-NC). After 24 h of transfection, the cells were harvested for MFF analysis via immunoblotting. 
E, A luciferase assay was performed in Cal-27 cells that were co-transfected with miR-593-5p mimics and reporter vectors carrying MFF 
3’UTR with wild type (MFF-wt-3’UTR) versus mutated (MFF-mut-3’UTR) miR-593-5p response element. **P < 0.001. F, miR-593-5p 
suppressed MFF expression with wild type but not mutated 3’UTR. Cal-27 cells were co-transfected with miR-593-5p mimics or control 
(miR-con) along with pcDNA3.1 cloned with a wild-type (MFF-wt-3’UTR) or mutatated (MFF-mut-3’UTR) MFF expression cassette at 
miR-593-5p response element. MFF levels were detected using immunoblotting.
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Figure 3: miR-593-5p regulates mitochondrial fission and apoptosis in Cal-27 cells. A, miR-593-5p prevents mitochondrial 
fission. Cal-27 cells were transfected with miR-593-5p mimics or miR-593-5p control (miR-con). After 24 h of transfection, the cells were 
treated with cisplatin for 24 h followed by staining with MitoTracker Red. Left panel: mitochondria were visualized via staining with 
mitoTracker Red. The scale bar equals 3 µm. Right panel: quantification of cells with mitochondrial fission. **P < 0.001 versus cisplatin 
alone. B, C and D, Apoptosis was detected via TUNEL assay, flow cytometry and caspase-3/7 assay. *P < 0.01 versus cisplatin alone; 
**P< 0.001 versus cisplatin alone. E, miR-593-5p attenuated MFF levels, mitochondrial fission and apoptosis in the presence of MFF 
with wild type 3’UTR (MFF-wt-3’UTR) but not its mutated 3’UTR (MFF-mut-3’UTR). Cal-27 cells were transfected with miR-593-5p 
mimics along with pcDNA3.1 plasmid carrying a wild-type (MFF-wt-3’UTR) or mutatated (MFF-mut-3’UTR) MFF expression cassette 
at miR-593-5p response element. MFF levels were analyzed via immunoblotting (upper panel). Mitochondrial fission and apoptosis were 
detected via staining with MitoTracker Red and TUNEL. **P< 0.001. F, MFF target protector reduces the inhibitory effect of miR-593-5p 
on mitochondrial fission and apoptosis. Cal-27 cells were transfected with miR-593-5p mimics, along with the target protector (MFF-TP-
miR-593-5p) or the control (MFF-TP-control). MFF was analyzed via immunoblotting (upper panel). Mitochondrial fission and apoptosis 
were detected via staining with MitoTracker Red and TUNEL. **P < 0.001.
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enforced expression of BRCA1 (Supplementary 
Figure S5C) downregulated or upregulated miR-593-
5p expression, respectively, and expressing exogenous 
BRCA1 attenuated the cisplatin-induced downregulation 
of miR-593-5p (Figure 4B). Furthermore, a chromatin 
immunoprecipitation (ChIP) quantitative PCR (qPCR) 
assay revealed that BRCA1 bound to binding site 3 (BS3) 
but not to the other binding sites under physiological 
conditions (Figure 4C). Cisplatin treatment led to a 
reduced association of BRCA1 with the miR-593-5p 
promoter in the BS3 region (Figure 4D); the luciferase 
reporter assay also demonstrated reduced miR-593-5p 
promoter activity after cisplatin exposure (Figure 4E). 
BRCA1 overexpression increased miR-593-5p promoter 
activity; this enhancement was reversed through mutations 
introduced into the BS3 region (Figure 4F). miR-593-5p 
is located within the intron of the SND1 gene, but SND1 
mRNA levels were not substantially altered after cisplatin 
treatment (Supplementary Figure S5D) or BRCA1 
overexpression (Supplementary Figure S5E). Together, 
these data suggest that BRCA1 can positively regulate 
miR-593-5p expression in Cal-27 cells.
The role of BRCA1 in miR-593-5p expression led 
us to question whether the BRCA1–miR-593-5p–MFF 
axis is functionally related to mitochondrial fission and 
cisplatin sensitivity in TSCC cells. Cisplatin-induced 
mitochondrial fission and apoptosis were attenuated by 
BRCA1 (Figure 5A-D) in a manner that was dependent 
on the level of MFF protein (Supplementary Figure 
S5F) in Cal-27 cells. The knockdown of miR-593-5p 
attenuated the BRCA1 inhibitory effect on the level of 
MFF protein, mitochondrial fission and apoptosis induced 
by cisplatin(Figure 5E and 5F, Supplementary Figure 
S5G). We also found that BRCA1 was downregulated 
after cisplatin treatment and that exogenous BRCA1 
attenuated mitochondrial fission and apoptosis as well as 
the miR-593-5p level and MFF protein level in Scc-9 cells 
(Supplementary Figure S6A-D). Taken together, BRCA1, 
miR-593-5p and MFF constitute an axis that regulates 
mitochondrial fission and cisplatin sensitivity in TSCC 
cells.
Meanwhile, we tested whether BRCA1–miR-593-
5p–MFF axis-dependent regulation was sensitivity to 
other DNA-damaging agents. We found that MFF protein 
expression was upregulated but the expression of miR-
593-5p and BRCA1 protein was downregulated when Cal-
27 and Scc-9 cells were treated with adriamycin (ADR) 
or camptothecin(CPT) (Supplementary Figure S7A). In 
addition, we found that overexpression of BRCA1 could 
attenuate the mitochondrial fission and apoptosis induced 
by ADR or CPT(Supplementary Figure S7B and S7C). 
These data suggest that chemosensitivity to other DNA-
damaging agents could also be regulated by the BRCA1–
miR-593-5p–MFF axis in TSCC cells. 
Tongue squamous cell carcinoma xenografts
We established three groups of TSCC xenografts to 
investigate whether the BRCA1–miR-593-5p–MFF axis 
could influence the apoptosis and cisplatin sensitivity of 
TSCC cells in vivo.
First, we found that MFF knockdown attenuated the 
inhibition of the tumor burden induced by cisplatin (Figure 
6A and 6B, Supplementary Figure S8A). Furthermore, 
MFF expression and apoptosis were attenuated by the 
stable expression of MFF shRNA in Cal-27 cells under 
cisplatin treatment (Figure 6C, Supplementary Figure 
S8A-C). These data suggest that MFF mediates the 
signal for apoptosis and cisplatin sensitivity in vivo. 
Cal-27 cells with stable miR-593-5p expression showed 
enhanced tumor growth in the presence of cisplatin 
(Figure 6D and 6E, Supplementary Figure S8D). We also 
found that miR-593-5p was upregulated but MFF and 
apoptosis were attenuated given the stable expression 
of miR-593-5p in xenografts after cisplatin treatment 
(Figure 6F, Supplementary Figure S8D-F). These results 
suggest that miR-593-5p inhibits apoptosis and cisplatin 
sensitivity in vivo by directly targeting MFF. Finally, in 
Cal-27 cells with stable BRCA1 expression, we observed 
that the inhibition of tumor growth (Figure 6G and 6H, 
Supplementary Figure S8G) was attenuated by BRCA1 in 
response to cisplatin treatment while BRCA1 expression 
and miR-593-5p levels were increased(Supplementary 
Figure S8H and 8I). MFF levels and apoptosis were 
attenuated by stable BRCA1 expression under cisplatin 
treatment (Figure 6I, Supplementary Figure S8G-I). These 
data suggest that BRCA1 could regulate apoptosis and 
cisplatin sensitivity in vivo through its downstream targets 
miR-593-5p and MFF. Taken together, the BRCA1-miR-
593-5p–MFF axis regulates cisplatin sensitivity through 
the mitochondrial fission pathway in vivo. 
High MFF expression and low miR-593-5p or 
BRCA1 expression are associated with cisplatin 
sensitivity and good patient prognosis
We evaluated the clinical significance of the 
BRCA1–miR-593-5p–MFF axis in cisplatin sensitivity 
as well as patient prognosis for TSCC. We performed a 
retrospective analysis of TSCC samples from 132 patients 
from three independent centers. According to previous 
studies [37], patients with a partial or complete response 
were defined as having cisplatin-sensitive tumors, 
whereas TSCC patients(TSCCs) with progressive disease 
or stable disease were defined as having non-sensitive 
or resistant tumors. Immunohistochemical staining and 
in situ hybridization demonstrated that MFF expression 
was higher and miR-593-5p and BRCA1 expression was 
lower in cisplatin-sensitive TSCC cells compared with 
non-sensitive cells (Figure 7A). Consequently, cisplatin-
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Figure 4: BRCA1 transactivates miR-593-5p. A, BRCA1 was analyzed using immunoblotting in Cal-27 cells under cisplatin 
treatment. B, BRCA1 attenuated the cisplatin-induced decrease of miR-593-5p. Cal-27 cells were transiently transfected with BRCA1 
expressing plasmids or empty vector (Vec) and then treated with cisplatin for 24h. miR-593-5p were detected using qRT-PCR (upper panel), 
whereas BRCA1 was analyzed using immunoblotting (lower panel). *P< 0.01 versus cisplatin alone. C, ChIP-qPCR analysis of BRCA1 
binding to the promoter of miR-593-5p in the BS3 region. **P< 0.001. D, ChIP-qPCR analysis of the association levels of BRCA1 with 
the miR-593-5p promoter in the BS3 region under cisplatin treatment. E, A luciferase assay indicated that cisplatin induced a reduction 
of miR-593-5p promoter activity in the BS3 region. Cal-27 cells were transfected with the wild-type promoter (wt) in the BS3 or empty 
vector (pGL3-Basic). F, A luciferase assay indicated that BRCA1 activated miR-593-5p promoter activity in the BS3 region. Cal-27 cells 
transiently transfected with BRCA1 expressing plasmids or empty vector (Vec) were treated with the wild-type promoter (wt) or a promoter 
with mutations in the BS3 (mut). **P< 0.001.
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sensitive TSCC cells presented a higher percentage of 
apoptotic cells than non-sensitive cells (Figure 7A). 
There was a significant difference in the expression 
profiles of chemosensitive and non-sensitive TSCCs, as 
determined by the percentage of positive cells (Figure 
7A). Additionally, a Spearman order correlation analysis 
showed that MFF expression in TSCC was inversely 
correlated with miR-593-5p (rs=-0.653, P<0.001) and 
BRCA1 levels (rs=-0.532, P < 0.001); however, miR-593-
5p expression correlated with BRCA1 levels (rs=0.535, 
P<0.001; Figure 7B).
Next, we analyzed the association of MFF, miR-593-
5p and BRCA1 expression with the clinicopathological 
status of TSCC patients (Table 1). No significant 
correlation was observed between MFF, miR-593-5p or 
BRCA1 expression and sex, age, lymph node status or 
clinical stage. However, MFF, miR-593-5p and BRCA1 
expression were significantly associated with cisplatin 
sensitivity. Tumors with cisplatin sensitivity expressed 
higher levels of MFF and lower levels of miR-593-5p and 
BRCA1. Moreover, we evaluated the correlation between 
MFF, miR-593-5p and BRCA1 expression and patient 
overall survival (OS). A univariate Cox regression analysis 
indicated that the patients with TSCC and a high MFF 
expression level or low miR-593-5p or BRCA1 levels 
had a longer OS (Table 2 and Figure 7C). The cumulative 
survival rate at 60 months was 46.67%, 44.87% and 
45.78% in patients with high MFF, low miR-593-5p and 
low BRCA1 expression, respectively; this rate was only 
24.56%, 25.93% and 22.45% in those with low MFF, high 
Figure 5: BRCA1 inhibits mitochondrial fission and apoptosis through miR-593-5p and MFF in Cal-27 cells. A, BRCA1 
attenuated mitochondrial fission in Cal-27 cells under cisplatin treatment. Cal-27 cells transiently transfected with BRCA1 expressing 
plasmids or vector control (Vec) were treated with cisplatin for 24h. Scale bar equals 3 µm. **P < 0.001 versus cisplatin alone. B, C and 
D, Apoptosis was detected using TUNEL, flow cytometry, and caspase-3/7 activity assays. *P < 0.01 versus cisplatin alone; **P < 0.001 
versus cisplatin alone. E, The knockdown of miR-593-5p leads to the attenuation of the BRCA1 inhibitory effect on MFF protein levels 
under cisplatin treatment. Cal-27 cells stably expressing BRCA1 or vector control (Vec) were transfected with miR-593-5p inhibitors or 
inhibitor-negative control (inhibitor-NC). MFF levels were analyzed using immunoblotting. F, Mitochondrial fission and apoptosis were 
detected via staining with MitoTracker Red and TUNEL.*P < 0.01.
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miR-593-5p and high BRCA1 expression, respectively 
(Table 1). Furthermore, a multivariate Cox regression 
analysis revealed that the high-level expression of MFF 
and low-level expression of BRCA1 is an independent 
prognostic factor for good OS in patients with TSCC 
(Table 2). Together, these data suggest that the BRCA1–
miR-593-5p–MFF axis correlates with cisplatin sensitivity 
and patient OS in TSCC. 
DISCUSSION
The present study shows that MFF regulates 
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Figure 6: BRCA1–miR-593-5p–MFF axis attenuates the cisplatin-induced inhibition of tumor growth in Cal-27 cell 
xenografts in BALB/c-nu mice. A, B, C, BALB/c-nu mice bearing Cal-27 cells with the stable expression of MFF shRNA or its 
scramble form (sc) were treated with saline or cisplatin. (A) Tumor growth curves for Cal-27 tumors treated with saline or cisplatin. (B) 
Representative photomicrographs of tumors from each group at day 35. (C) Apoptosis was detected via TUNEL assay. n=6 for each group. 
For TUNEL assay, n=24 slices from 6 xenograft tumors were sampled per group. Bar=20 µm; #P < 0.05 versus cisplatin alone. D, E, F, 
BALB/c-nu mice bearing Cal-27 cells with the stable expression of miR-593-5p or its control (con) were treated with saline or cisplatin. (D) 
Tumor growth curves for Cal-27 tumors treated with saline or cisplatin. (E) Representative photomicrographs of tumors from each group 
at day 35. (F) Apoptosis was detected via TUNEL assay. n=6 for each group. For TUNEL assay, n=24 slices from 6 xenograft tumors were 
sampled per group. Bar=20 µm; #P < 0.05 versus cisplatin alone. G, H, I, BALB/c-nu mice bearing Cal-27 cells with the stable expression 
of BRCA1 or empty vector (Vec) were treated with saline or cisplatin. (G) Tumor growth curves for Cal-27 tumors treated with saline or 
cisplatin. (H) Representative photomicrographs of tumors from each group at day 35. (I) Apoptosis was detected via TUNEL assay. n=6 
for each group. For TUNEL assay, n=24 slices from 6 xenograft tumors were sampled per group. Bar=20 µm; #P <  0.05 versus cisplatin 
alone; *P< 0.01 versus cisplatin alone.
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Figure 7: Expression of MFF, miR-593-5p and BRCA1 correlates with cisplatin sensitivity and survival of TSCC 
patients(TSCCs). A, MFF, miR-593-5p and BRCA1 expression and apoptosis were demonstrated in cisplatin-sensitive versus non-
sensitive TSCCs. Left panel: MFF and BRCA1 expression were analyzed via immunohistochemistry; miR-593-5p expression was analyzed 
using in situ hybridization (×200). Apoptosis was detected using a TUNEL assay. Bar=20 µm. Right panel: Quantification of MFF, miR-
593-5p and BRCA1 expression in cisplatin-sensitive versus non-sensitive TSCCs. #P < 0.05; *P < 0.01. B, Associations between MFF, 
miR-593-5p and BRCA1 expression in TSCCs were analyzed via Spearman order correlation. C, Kaplan-Meier survival curves for TSCCs 
are plotted for MFF, miR-593-5p and BRCA1 expression, and survival differences were analyzed using a log-rank test. D, Model of 
the BRCA1–miR-593-5p–MFF axis in regulating mitochondrial fission and cisplatin sensitivity. The dotted line indicates the commonly 
accepted mechanism of BRCA1 regulation of cisplatin sensitivity, whereas the solid line represents the novel mechanism of BRCA1-
mediated cisplatin sensitivity identified in the present study.
Oncotarget14898www.impactjournals.com/oncotarget
mitochondrial fission and consequent cisplatin sensitivity. 
miR-593-5p, which is downregulated in response to 
cisplatin exposure, can inhibit MFF expression as well 
as mitochondrial fission by targeting MFF. We explored 
the mechanism by which miR-593-5p expression is 
regulated and found BRCA1 can transactivate miR-593-5p 
expression and inhibit MFF expression and the consequent 
mitochondrial fission through transcriptionally targeting 
miR-593-5p. Our results reveal a novel regulatory model 
of mitochondrial fission that affects cisplatin sensitivity 
via miRNA and BRCA1 in cancer cells.
In vertebrates, the target specificity of miRNAs 
is regulated by the requirement of small sequence 
complementarity between bases 2 and 8 of the miRNA and 
a corresponding seven-nucleotide sequence in the 3’UTR 
of the target mRNA [38]. The ability of a single miRNA 
to affect the expression of a wide variety of proteins has 
led to increased interest in miRNAs as mediators of the 
cellular response to cisplatin stimulation, and numerous 
miRNAs have been identified [33, 39]. However, no 
miRNAs have been identified as regulating mitochondrial 
fission and consequent cisplatin sensitivity. We found 
that MFF is a direct target of miR-593-5p and that miR-
593-5p inhibits cisplatin sensitivity in TSCC through its 
suppression of MFF expression.
It has been demonstrated that approximately 50% 
of miRNAs are predicted to be expressed from the introns 
of protein-coding transcripts [40]. Accordingly, intronic 
miRNAs may be transcribed as part of their host genes 
or transcribed independently using their own promoters. 
Ongoing studies have revealed that one-third of intronic 
miRNAs have transcription initiation regions that are 
separate from the promoters of their host genes [41]. 
Strikingly, miR-593-5p is an intronic miRNA in the SND1 
gene; we identified the binding site of BRCA1 to be within 
the SND1 gene, and BRCA1 consistently influenced 
the expression of miR-593-5p, but not of SND1, in our 
findings.
The chemotherapeutic drug cisplatin primarily 
acts against cancer by damaging DNA and is used in 
the treatment of many solid tumors. BRCA1 is a tumor 
suppressor gene located on chromosome 17q21 that has 
been intensively investigated as participating in the repair 
of cisplatin-induced DNA double-strand breaks [42]. 
Accordingly, a decrease in BRCA1 expression leads to a 
decreased proficiency in DNA repair, increased cisplatin 
sensitivity and improved survival in non-small cell lung 
cancer [43, 44], breast cancer [45], advanced esophageal 
squamous cell carcinoma [46] and ovarian cancer [47] 
patients. However, it is currently unknown whether 
BRCA1 expression correlates with cisplatin sensitivity in 
TSCC. In this study, we found that cisplatin decreased the 
level of BRCA1 in TSCC patients and that reduction of 
BRCA1 was positively correlated with overall survival. 
Notably, the mechanism of BRCA1 downregulation 
by cisplatin remains poorly understood, a few previous 
studies demonstrated that BRCA1 can be downregulated 
at translation [48,49] or transcription levels [50, 51] by 
cisplatin. Recent studies found BRCA1 was a direct 
targets of miR-638 [48] and miR-9 [49] and BRCA1 
protein decreased upon cisplatin treatment. However, the 
mechanism of BRCA1 mRNA downregulation has not 
been clear, there may be a TP53-sensitive component [50] 
or EZH2-dependent [51] which need to be verified in the 
further studies. 
In addition to its role in DNA repair, BRCA1 
also has multiple roles in cellular functions, such as 
transcriptional regulation. The transcriptional activity of 
the C-terminal region of BRCA1 was first identified when 
it was fused with the GAL4 DNA-binding domain [52]. 
Recent studies have firmly established the role of BRCA1 
as a transcriptional activator and transcriptional repressor 
[53]. A recent study identified the direct transcriptional 
targets of BRCA1 by combining gene expression data 
with BRCA1 binding sites detected using ChIP-chip 
analysis. However, the results suggested that only 44 
out of the 1,294 transcriptional targets may be directly 
regulated by BRCA1 [54]. Whether BRCA1 binds to DNA 
directly or indirectly has been extensively debated, but it 
is accepted that BRCA1 interacts with DNA not only to 
repair damaged DNA but also to regulate transcription. 
Our results suggest that BRCA1 has a novel role in the 
regulation of mitochondrial fission and cisplatin sensitivity 
through transactivating miR-593-5p expression in TSCC 
cells. 
The present study reveals a link between the 
BRCA1-miR-593-5p-MFF axis and the mitochondrial 
fission program of TSCC (Figure 7D). Future studies are 
needed to elucidate how this pathway is integrated into 
the DNA repair pathway and its relationship with other 
intrinsic apoptotic factors. Notably, clinical evidence 
suggests that BRCA1, miR-593-5p and MFF levels predict 
cisplatin sensitivity, and the modulation of this axis may 
provide a therapeutic approach for upregulating cisplatin 
sensitivity. 
MATERIALS AND METHODS
Cell culture
The human tongue cancer cell lines Cal-27 and 
Scc-9 were purchased from the American Type Culture 
Collection. Cal-27 cells were cultivated in Dulbecco’s 
modified Eagle’s medium (Gibco, Rockville, MD, USA) 
supplemented with 10% fetal bovine serum (Invitrogen, 
Carlsbad, CA, USA). Scc-9 cells were cultivated in 
Dulbecco’s modified Eagle’s medium-F12 (Gibco) 
supplemented with 10% fetal bovine serum. 
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ChIP assays
ChIP assays were performed as previously described 
with some modifications [15,54]. The antibodies used for 
immunoprecipitation were rabbit IgG (sc-805, Santa Cruz) 
and BRCA1 (ab16780; Abcam). In brief, Cal-27 cells 
(5×106) were washed with PBS and incubated for 10 min 
with 1% formaldehyde at room temperature. The cross-
linking was halted with 0.1 M glycine for 5 min. The cells 
were washed twice with PBS and lysed for 1 h at 4°C in a 
lysis buffer and then sonicated into chromatin fragments 
with an average length of 500-800 bp as assessed via 
agarose gel electrophoresis. The samples were precleared 
with Protein-A agarose (Roche) for 1 h at 4°C on a rocking 
platform, and 5 µg of specific antibodies were added and 
rocked overnight at 4°C. Immunoprecipitated DNA was 
purified using the QIAquick PCR purification kit (Qiagen) 
according to the manufacturer’s protocol. The final ChIP 
DNA was then used as a template in qPCR reactions using 
primers that encompass ten possible BRCA1 binding 
sites of the homo miR-593-5p promoter. The primers are 
presented in Supplementary Table S1. The specificity 
of the PCR amplification was confirmed via agarose gel 
electrophoresis.
Transfections
MFF siRNAs (E-018261) and BRCA1 siRNAs (E-
003461) were obtained from GE Dharmacon. miR-593-
5p mimics and inhibitors were obtained from Ribobio 
(Guangzhou, China). Cells were transfected using 
Lipofectamine 2000 (Invitrogen). 
Plasmid construction and establishment of stable 
cell lines
An MFF shRNA retrovirus vector (pSR-puro-
MFF1 shRNA, 37247) [55] and a BRCA1 (pBABE-
puro HA BRCA1, 14999) [56] retrovirus vector were 
obtained from Addgene (MA, USA). BRCA1 was also 
cloned into pcDNA3.1 to generate pcDNA-BRCA1. The 
primers to amplify BRCA1 were as follows: forward: 
5’-TAGATATCATGGATTTATCTGCTCTTCGC-3’ 
and reverse: 
5’-CTCTCGAGTCAGTAGTGGCTGTGGGGGA-3’. 
MFF CDS region was amplified by 
PCR using the forward primer 5’- 
CAGGATCCATGAGTAAAGGAACAAGCAGTGA-3’, 
the reverse primer: 
5’-TACTCGAGCTAGCGGCGAAACCAGAGC-3’, and 
then cloned into pcDNA3.1.
Recombinant retrovirus was generated by co-
transfecting pSuper-Retro-Puro carrying the shRNA 
expression cassette with helper plasmid pIK in 293T cells 
for 48 h. The viral supernatants were collected, filtered, 
mixed with fresh complete medium (1:1) and 4 µg/mL 
of polybrene (Sigma, St Louis, Missouri, USA), and then 
added to Cal-27 or Scc-9 TSCC cells. The stably infected 
cells were selected with 2µg/mL of Puromycin (Sigma, St 
Louis, Missouri, USA) for two weeks.
Lentiviral plasmid (pLVX-mCMV-tdTomato-PGK-
Puro) delivering miR-593 precursors were bought from 
BioWit Technologies (Shenzhen, China). The viruses were 
amplified in HEK293 cells. Lentiviral infection of the Cal-
27 cell line was performed as previously described [57].
Luciferase reporter assay
We cloned MFF expression cassette containing miR-
593-5p targeting site (wide type or mutated) into the pGL3-
Control plasmid downstream of the luciferase reporter 
gene. In addition, we cloned miR-593-5p promoter region 
containing the BRCA1 binding site sequence (wild type 
or mutated) into the pGL3-Basic plasmid upstream of 
the luciferase reporter gene. Luciferase activities were 
measured using a luciferase assay kit (Promega, Madison, 
WI, USA), and the target effect was expressed as the 
relative luciferase activity of the reporter vector with the 
target sequence over that without the target sequence.
Target protector preparation and transfection
The target protector (TP) was designed 
and named as others described [15,34]. In brief, 
the MFF-TP miR-593-5p sequence was 5’- 
CGACATAAGTGCAGACTCGTCAAGA-3’. 
The MFF-TP control was 5’- 
CGAGATAACTCCACACTCCTCAAGA -3’. The 
sequences were obtained from Gene Tools. Transfection 
of the target protector was performed using an Endo-
Porter kit (Gene Tools) according to the manufacturer’s 
instructions.
Isolation of mitochondria and cytosol
Subcellular fractions were prepared as described 
previously [16]. In brief, the cells were washed twice with 
cold PBS, and the pellet was suspended in 0.2 ml of buffer 
(20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 
1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol (DTT), 
0.1 mM phenylmethylsulfonyl fluoride (PMSF), and 250 
mM sucrose) containing a protease inhibitor cocktail. 
Then, the cells were homogenized with 12 strokes in a 
Dounce homogenizer, followed by centrifugation twice 
at 750 g for 5 min at 4 °C to collect nuclei and debris. 
The mitochondria-enriched heavy membrane pellet was 
collected with further centrifugation at 10,000 g for 15 min 
at 4 °C; the supernatants were collected as the cytosolic 
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fractions. 
Apoptosis assay
Cal-27 and Scc-9 cells were treated with the IC
50
 
of cisplatin(Sigma, USA) for 24 hours for an apoptosis 
assay [37,58]. Additionally, Cal-27 and Scc-9 cells were 
treated with 2×10-6 M adriamycin(ADR) (Sigma, USA) 
or 15×10-6 M camptothecin(CPT) (Sigma, USA) for 24 
hours for an apoptosis assay. TUNEL technology was 
performed using a kit from Roche (Cat.No.11684795910). 
The detection procedures were in accordance with the kit 
instructions. Sections were examined with an ImagerZ1 
microscope (Zeiss, Jena, Germany). An investigator blind 
to the treatment quantified 20 random fields of samples. 
Caspase-3/7 activity was determined using an Apo-ONE® 
Homogeneous Caspase-3/7 assay kit from Promega 
according to the manufacturer’s protocol. Flow cytometry 
was performed using Annexin V and propidium iodide 
double staining (Sigma-Aldrich).
MTT assay
To monitor the IC50 of cisplatin, Cal-27 and Scc-9 
cells were treated with cisplatin atdifferent concentrations 
for 24 hours. An MTT assay was performed as described 
previously [37]. The data were analyzed with the software 
origin 7.5 (OriginLab, Northampton, MA, USA) to fit a 
sigmoidal curve. The IC
50
 is considered to be the cisplatin 
concentration that reduces cell proliferation by 50%. The 
IC50 values of cisplatin for Cal-27 and Scc-9 cells were 
8×10-6 and 1.8×10-5 M, respectively. 
Immunofluorescence staining
Cells on coverslips were stained for MFF and 
cytochrome c(CYTO c). After mitochondrial staining, the 
cells were incubated with primary antibodies against MFF 
(ab81127, Abcam) or cytochrome c (sc-13560, Santa Cruz) 
and then incubated with rhodamine- or FITC-conjugated 
secondary antibodies (Invitrogen). The coverslips were 
counterstained with 46-diamidino-2-phenyl indole and 
imaged under a confocal microscope TCS SP5 (Lecia, 
Solms, Germany).
Mitochondrial staining and analysis of 
mitochondrial fission
Mitochondrial staining was performed as described 
previously [15,16], with modifications. Briefly, cells 
were plated onto coverslips and treated under different 
conditions. Then, they were stained for 30 min with 0.1 
µM MitoTracker Red CMXRos (Molecular Probes). 
The mitochondria were imaged using a laser-scanning 
confocal TCS SP5 microscope (Lecia, Solms, Germany). 
The assessment and quantification of mitochondrial 
morphology were performed as described previously[59]. 
Briefly, the extent of mitochondrial fission was analyzed 
on a cell-to-cell basis. Mitochondria fission was calculated 
as the percentage of cells with fragmented mitochondria 
relative to the total number of cells, which were randomly 
selected and scored. A punctiform mitochondrial 
phenotype was scored as a fragmented mitochondrion 
when at least 90% of its tubular mitochondria were 
disintegrated. At least 200 randomly selected cells in 
multiple fields were assessed. 
Quantitative real-time PCR (qRT-PCR)
Total RNA was prepared using TRIzol reagent 
(Invitrogen). The quantitative detection of MFF, SND1 and 
β-actin was performed via qRT-PCR using SYBR Green 
Real-time PCR Master Mix (ReverTra Ace, Toyobo) and 
a LightCycler 480 (Roche, Basel, Switzerland) according 
to the manufacturer’s instructions. The sequences of MFF 
primers were 5’ -CACCACCTCGTGTACTTACGC-3’ 
(forward) and 5’ -CCGCTCTCTTTTTAGTCTGCC-3’ 
(reverse). The sequences of the SND1 primers were 
5’-CAAATCAGGAAGAAACATCAAAGAC-3’ 
(forward) and 
5’-AATCACATAATCAACAGTTGGACAG-3’ 
(reverse). The sequences of the β-actin primers were 
5’-AGCCTCGCCTTTGCCGATCC-3’ (forward) and 
5’-ACATGCCGGAGCCGTTGTCG-3’ (reverse). The 
primers for miR-593-5p and U6 detection assays were 
purchased from Ribobio.
Western blotting
Immunoblotting was performed as previously 
described[37]. Briefly, cells were lysed for 0.5 h at 4°C 
in a RIPA Buffer (R0278, Sigma) containing a protease 
inhibitor cocktail. Protein extracts were resolved through 
8% SDS-polyacrylamide gel electrophoresis, transferred 
to polyvinylidene difluoride membranes (BioRad, 
Berkeley, CA, USA), probed with antibody against human 
MFF (ab81127), DRP1 (ab56788), FIS1 (ab71498), 
TOM20(ab78547), BRCA1 (ab16780; Abcam), MFN1 
(sc-50330), MFN2 (sc-50331), OPA1 (sc-393296), 
COXIV(sc-376731), cytochrome c (sc-13560) (Santa 
Cruz), β-actin (Proteintech, Chicago, IL, USA) or Tubulin 
(sc-53646) and then with a peroxidase-conjugated 
secondary antibody (Proteintech); they were visualized 
via chemiluminescence (GE, Fairfield, CT, USA).
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In situ hybridization
In situ hybridization was performed as previously 
described[37] according to the manufacturer’s protocol 
(Exiqon, Vedbaek, Denmark). Briefly, after demasking, 
miR-593-5p was hybridized to 5’ DIG-labeled 
LNAprobes. Then, the digoxigenins were recognized via 
a specific anti-DIG antibody that is directly conjugated 
to alkaline phosphatase. The nuclei were counterstained 
with Kernechtrot Solution (N3020, Sigma). In all, 5×200 
tumor cells were counted randomly in each section. The 
sections with more than 300 miR-593-5p-positive cells 
were considered to have high miR-593-5p expression.
Immunohistochemistry
For immunohistochemistry [37], TSCC sections 
were incubated with MFF (ab81127) and BRCA1 
(ab16780, Abcam) antibodies at 4 °C overnight. The 
sections were then treated with a secondary antibody, 
followed by further incubation with streptavidin-
horseradish peroxidase complex. Diaminobenzidine 
(Dako, Carpinteria, CA, USA) was used as a chromogen, 
and the nuclei were counterstained with hematoxylin. A 
total of 5×200 tumor cells were counted in each section. 
Sections with more than 350 MFF- or BRCA1-positive 
cells were considered to have high MFF or BRCA1 
expression.
Patient and tissue samples
Specimens of locally advanced TSCCs (n=132) 
were obtained from three independent centers, including 
the Department of Oral and Maxillofacial Surgery of Sun 
Yat-sen Memorial Hospital (n=53), the Affiliated Hospital 
of North Sichuan Medical College (n=45) and the West 
China Hospital (n=34) between Jan 1, 2002, and Dec 31, 
2008. The patients were treated with cisplatin prior to 
surgery. According to the ‘Response Evaluation Criteria 
in Solid Tumors’ of the World Health Organization, 
TSCCs with progressive disease or stable disease response 
was designated to be cisplatin-resistant or non-sensitive 
TSCC, whereas TSCCs that showed a partial or complete 
response was determined to be cisplatin-sensitive TSCC. 
The tissues were obtained from the respective pathology 
departments, and histological diagnosis and scoring 
of all the cases were performed by two independent 
pathologists. Survival time was calculated from the date 
of surgery to the date of death or to the last follow-up. The 
date of death was obtained from patient records or through 
follow-up telephone calls. This study was approved by the 
institutional ethical review boards of three hospitals, and 
written informed consent was obtained from all patients.
Tumor xenografts
A TSCC xenograft mouse model was used to 
evaluate in vivo cisplatin sensitivity. Male BALB/c-
nu mice 4 to 6 weeks old were prepared for tumor 
implantation. All animals were maintained in a sterile 
environment on a daily 12 h light/12 h dark cycle. Cal-
27 cells with stable expression of MFF, miR-593-5p and 
BRCA1 were used. After resuspension in 150 μL of PBS, 
Cal-27 cells (5×106/mouse) were injected subcutaneously 
into the flanks of the nude mice. One week after 
implantation, when the tumor became palpable at a size of 
~2 mm in diameter, cisplatin (5 mg/kg) was administered 
via intraperitoneal injections every three days from days 
8 to 32. Tumor volume was calculated at the day of 
cisplatin injection according to the following formula: 
TV (mm3)=length × width2×0.5. At day 35, the primary 
tumors were carefully removed, imaged, and analyzed 
via immunohistochemistry, in situ hybridization, western 
blotting and qRT-PCR. 
Statistics
All statistical analyses were performed using SPSS 
19.0. Student’s t-test and the Chi-square test were used to 
analyze the relationship between MFF, miR-593-5p and 
BRCA1 expression and clinicopathological characteristics. 
To measure the association between pairs of variables, 
Spearman order correlations were performed. Kaplan-
Meier survival curves were plotted, and a log-rank test 
was performed. All experiments for cell cultures were 
performed in at least three independent experiments. 
The data are expressed as the means ± SEM. P<0.05 was 
considered significant.
ACKNOWLEDGMENTS
This work was supported by National Natural 
Science Foundation of China (81472521, 81272951 and 
81072225 to J.-S. L., 81172563 to W.-L. C., 81402251 to 
S. F., 81302369 to L.-J.S.), by Natural Science Foundation 
of Guangdong Province(10251008901000022 to J.-S. L.), 
by China Postdoctoral Science Foundation (2012M521649 
to J.-S. L.), by Specialized Research Fund for the Doctoral 
Program of Higher Education (20110171110068 to J.-S. 
L.), by Science and Technology Project of Guangzhou 
City (2012J4100078 to J.-S. L.), by Fundamental Research 
Funds for the Central Universities (13ykpy27 to L.-J.S.), 
by Fund for Excellent Doctoral Dissertation of Guangdong 
Province (81000-3212502 to L.-J.S.).
CONFLICTS OF INTEREST
None.
Oncotarget14902www.impactjournals.com/oncotarget
REFERENCES
1. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, 
Kepp O, Castedo M, Kroemer G. Molecular mechanisms of 
cisplatin resistance. Oncogene. 2012;31:1869-83.
2. Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, 
Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, 
Wang ZH, et al. Randomized phase III trial of induction 
chemotherapy with docetaxel, cisplatin, and fluorouracil 
followed by surgery versus up-front surgery in locally 
advanced resectable oral squamous cell carcinoma. J Clin 
Oncol. 2013;31:744-51. 
3. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, 
Ensley J, Forastiere AA; Eastern Cooperative Oncology 
Group. Randomized phase III evaluation of cisplatin plus 
fluorouracil versus cisplatin plus paclitaxel in advanced 
head and neck cancer (E1395): an intergroup trial of the 
Eastern Cooperative Oncology Group. J Clin Oncol. 
2005;23:3562-7.
4. Kartalou M, Essigmann JM. Mechanisms of resistance to 
cisplatin. Mutat Res. 2001;478:23-43.
5. McBride HM, Neuspiel M, Wasiak S. Mitochondria: more 
than just a powerhouse. Curr Biol. 2006;16:R551-60.
6. Cipolat S, Rudka T, Hartmann D, Costa V, Serneels L, 
Craessaerts K, Metzger K, Frezza C, Annaert W, D’Adamio 
L, Derks C, Dejaegere T, Pellegrini L, et al. Mitochondrial 
rhomboid PARL regulates cytochrome c release during 
apoptosis via OPA1-dependent cristae remodeling. Cell. 
2006;126:163-75.
7. Sanchis D, Mayorga M, Ballester M, Comella JX. Lack 
of Apaf-1 expression confers resistance to cytochrome 
c-driven apoptosis in cardiomyocytes. Cell Death Differ. 
2003;10:977-86.
8. Tait SW, Parsons MJ, Llambi F, Bouchier-Hayes L, 
Connell S, Muñoz-Pinedo C, Green DR. Resistance to 
caspase independent cell death requires persistence of intact 
mitochondria. Dev Cell. 2010;18:802-13. 
9. Suen DF, Norris KL, Youle RJ. Mitochondrial dynamics 
and apoptosis. Genes Dev. 2008;22:1577-90.
10. Yang Y, Ouyang Y, Yang L, Beal MF, McQuibban A, 
Vogel H, Lu B. Pink1 regulates mitochondrial dynamics 
through interaction with the fission/fusion machinery. Proc 
Natl Acad Sci USA. 2008;105:7070-5.
11. Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, 
McCaffery JM, Chan DC. Mitochondrial fusion is required 
for mtDNA stability in skeletal muscle and tolerance of 
mtDNA mutations. Cell. 2010;141:280-9.
12. Verhoeven K, Claeys KG, Züchner S, Schröder JM, Weis J, 
Ceuterick C, Jordanova A, Nelis E, De Vriendt E, Van Hul 
M, Seeman P, Mazanec R, Saifi GM, et al. MFN2 mutation 
distribution and genotype/phenotype correlation in Charcot-
Marie-Tooth type 2. Brain. 2006;129:2093-102.
13. Chen H, McCaffery JM, Chan DC. Mitochondrial fusion 
protects against neurodegeneration in the cerebellum. Cell. 
2007;130:548-62.
14. Brooks C, Wei Q, Cho SG, Dong Z. Regulation of 
mitochondrial dynamics in acute kidney injury in cell 
culture and rodent models. J Clin Invest. 2009;119:1275-85.
15. Wang K, Long B, Jiao JQ, Wang JX, Liu JP, Li Q, Li PF. 
miR-484 regulates mitochondrial network through targeting 
FIS1. Nat Commun. 2012;3:781.
16. Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, Li 
YR, Li PF. miR-499 regulates mitochondrial dynamics by 
targeting calcineurin and dynamin-related protein-1. Nat 
Med. 2011;17:71-8.
17. Tait SW, Green DR. Mitochondria and cell death: outer 
membrane permeabilization and beyond. Nat Rev Mol Cell 
Biol. 2010;11:621-32.
18. Westermann B. Mitochondrial fusion and fission in cell life 
and death. Nat Rev Mol Cell Biol. 2010 ;11:872-84.
19. Sheridan C, Delivani P, Cullen SP, Martin SJ. Bax- or 
Bak-induced mitochondrial fission can be uncoupled from 
cytochrome c release. Mol Cell. 2008;31:570-85.
20. Brooks C, Cho SG, Wang CY, Yang T, Dong Z. 
Fragmented mitochondria are sensitized to Bax insertion 
and activation during apoptosis. Am J Physiol Cell Physiol. 
2011;300:C447-55.
21. Farrand L, Kim JY, Im-Aram A, Suh JY, Lee HJ, Tsang 
BK. An improved quantitative approach for the assessment 
of mitochondrial fragmentation in chemoresistant ovarian 
cancer cells. PLoS One. 2013;8:e74008.
22. Tamura Y, Itoh K, Sesaki H. SnapShot: Mitochondrial 
dynamics. Cell. 2011;145:1158, 1158.e1.
23. Qian W, Wang J, Van Houten B. The role of dynamin-
related protein 1 in cancer growth: a promising therapeutic 
target? Expert Opin Ther Targets. 2013;17:997-1001.
24. Chiang YY, Chen SL, Hsiao YT, Huang CH, Lin TY, 
Chiang IP, Hsu WH, Chow KC. Nuclear expression of 
dynamin-related protein 1 in lung adenocarcinomas. Mod 
Pathol. 2009;22:1139-50.
25. Lee YJ, Jeong SY, Karbowski M, Smith CL, Youle RJ. 
Roles of the mammalian mitochondrial fission and fusion 
mediators FIS1, DRP1, and Opa1 in apoptosis. Mol Biol 
Cell. 2004;15:5001-11.
26. Palmer CS, Osellame LD, Laine D, Koutsopoulos OS, 
Frazier AE, Ryan MT. MiD49 and MiD51, new components 
of the mitochondrial fission machinery. EMBO Rep. 
2011;12:565-73.
27. Suzuki M, Jeong SY, Karbowski M, Youle RJ, Tjandra 
N. The solution structure of human mitochondria fission 
protein FIS1 reveals a novel TPR-like helix bundle. J Mol 
Biol. 2003;334:445-58.
28. Zhao J, Liu T, Jin S, Wang X, Qu M, Uhlén P, Tomilin 
N, Shupliakov O, Lendahl U, Nistér M. Human MIEF1 
recruits DRP1 to mitochondrial outer membranes and 
promotes mitochondrial fusion rather than fission. EMBO 
J. 2011;30:2762-78.
29. Otera H, Wang C, Cleland MM, Setoguchi K, Yokota 
Oncotarget14903www.impactjournals.com/oncotarget
S, Youle RJ, Mihara K. MFF is an essential factor for 
mitochondrial recruitment of DRP1 during mitochondrial 
fission in mammalian cells. J Cell Biol. 2010;191:1141-58.
30. Friedman JR, Lackner LL, West M, DiBenedetto 
JR, Nunnari J, Voeltz GK. ER tubules mark sites of 
mitochondrial division. Science. 2011;334:358-62.
31. Gandre-Babbe S, van der Bliek AM. The novel tail-
anchored membrane protein MFF controls mitochondrial 
and peroxisomal fission in mammalian cells. Mol Biol Cell. 
2008;19:2402-12.
32. Strack S, Cribbs JT. Allosteric modulation of DRP1 
mechanoenzyme assembly and mitochondrial fission by the 
variable domain. J Biol Chem. 2012;287:10990-1001.
33. Drayton RM. The role of microRNA in the response to 
cisplatin treatment. Biochem Soc Trans. 2012;40:821-5.
34. Choi WY, Giraldez AJ, Schier AF. Target protectors reveal 
dampening and balancing of Nodal agonist and antagonist 
by miR-430. Science. 2007;318:271-4.
35. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a 
functions downstream of NFATc3 to regulate cardiac 
hypertrophy. Proc Natl Acad Sci USA. 2009;106:12103-8.
36. Zhao Y, Samal E, Srivastava D. Serum response factor 
regulates a muscle-specific microRNA that targets Hand2 
during cardiogenesis. Nature. 2005;436:214-20.
37. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, 
Chen W, Pan C, Liu Q, Song E, Li J. MiR-200b and 
miR-15b regulate chemotherapy-induced epithelial-
mesenchymal transition in human tongue cancer cells by 
targeting BMI1 .Oncogene. 2012;31:432-45.
38. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge 
CB. Prediction of mammalian microRNA targets. Cell. 
2003;115:787-98.
39. Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi 
E, Alberti P, Valeri B, Libra M, Barbareschi M, Raspagliesi 
F, Mezzanzanica D, Canevari S. Identification of a 
chrXq27.3 microRNA cluster associated with early relapse 
in advanced stage ovarian cancer patients. Oncotarget. 
2011;2:1265-78.
40. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. 
Identification of mammalian microRNA host genes and 
transcription units. Genome Res. 2004;14:1902-10.
41. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, 
Zhang X, Song JS, Fisher DE. Chromatin structure analyses 
identify miRNA promoters. Genes Dev. 2008;22:3172-83.
42. Stordal B, Davey R. A systematic review of genes involved 
in the inverse resistance relationship between cisplatin and 
paclitaxel chemotherapy: role of BRCA1.Curr Cancer Drug 
Targets. 2009;9:354-65.
43. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, 
Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, 
Maestre J. BRCA1 mRNA expression levels as an indicator 
of chemoresistance in lung cancer. Hum Mol Genet. 
2004;13:2443-9.
44. Bonanno L, Costa C, Majem M, Sanchez JJ, Gimenez-
Capitan A, Rodriguez I, Vergnenegre A, Massuti B, 
Favaretto A, Rugge M, Pallares C, Taron M, Rosell R. The 
predictive value of 53BP1 and BRCA1 mRNA expression 
in advanced non-small-cell lung cancer patients treated 
with first-line platinum-based chemotherapy. Oncotarget. 
2013;4:1572-81.
45. Lambie H, Miremadi A, Pinder SE, Bell JA, Wencyk P, 
Paish EC, Macmillan RD, Ellis IO. Prognostic significance 
of BRCA1 expression in sporadic breast carcinomas. J 
Pathol. 2003;200:207-13.
46. Gao Y, Zhu J, Zhang X, Wu Q, Jiang S, Liu Y, Hu Z, Liu 
B, Chen X. BRCA1 mRNA Expression as a Predictive and 
Prognostic Marker in Advanced Esophageal Squamous 
Cell Carcinoma Treated with Cisplatin- or Docetaxel-
Based Chemotherapy/Chemoradiotherapy. PLoS One. 
2013;8:e52589.
47. Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, 
Zahn C, Armstrong DK, Birrer MJ, Krivak TC. BRCA1 
expression and improved survival in ovarian cancer patients 
treated with intraperitoneal cisplatin and paclitaxel: a 
Gynecologic Oncology Group Study. Br J Cancer. 
2013;108:1231-7.
48. Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, Teal CB, 
Man YG, Brem RF, Fu SW. miR-638 mediated regulation 
of BRCA1 affects DNA repair and sensitivity to UV and 
cisplatin in triple-negative breast cancer. Breast Cancer Res. 
2014 ;16:435.
49. Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, 
Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G. miR-9 
regulation of BRCA1 and ovarian cancer sensitivity 
to cisplatin and PARP inhibition. J Natl Cancer Inst. 
2013;105:1750-8.
50. Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, 
Lamszus K, Goldberg ID, Rosen EM. Regulation of BRCA1 
and BRCA2 expression in human breast cancer cells by 
DNA-damaging agents. Oncogene. 1998;16(17):2229-41.
51. Li T, Cai J, Ding H, Xu L, Yang Q, Wang Z. EZH2 
participates in malignant biological behavior of epithelial 
ovarian cancer through regulating the expression of 
BRCA1. Cancer Biol Ther. 2014;15:271-8.
52. Monteiro AN, August A, Hanafusa H. Evidence for a 
transcriptional activation function of BRCA1 C-terminal 
region. Proc Natl Acad Sci USA .1996;93:13595-9.
53. Chang S, Sharan SK. The role of epigenetic transcriptional 
regulation in BRCA1-mediated tumor suppression. 
Transcription. 2013;4:24-8.
54. Gorski JJ, Savage KI, Mulligan JM, McDade SS, Blayney 
JK, Ge Z, Harkin DP. Profiling of the BRCA1 transcriptome 
through microarray and ChIP-chip analysis. Nucleic Acids 
Res. 2011;39:9536-48.
55. Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, 
Counter CM. RALA and RALBP1 regulate mitochondrial 
fission at mitosis. Nat Cell Biol. 2011;13:1108-15.
56. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of 
Oncotarget14904www.impactjournals.com/oncotarget
ATM-dependent phosphorylation of brca1 in the DNA 
damage response to double-strand breaks. Science. 1999; 
286: 1162-6.
57. Wang J, Guan X, Guo F, Zhou J, Chang A, Sun B, Cai Y, 
Ma Z, Dai C, Li X, Wang B. miR-30e reciprocally regulates 
the differentiation of adipocytes and osteoblasts by directly 
targeting low-density lipoprotein receptor-related protein 6. 
Cell Death Dis. 2013; 4:e845.
58. Kotowski U, Heiduschka G, Brunner M, Erovic BM, 
Martinek H, Thurnher D. Arsenic trioxide enhances the 
cytotoxic effect of cisplatin in head and neck squamous cell 
carcinoma cell lines. Oncol Lett. 2012;3:1326-1330.
59. Tanaka A, Youle RJ. A chemical inhibitor of DRP1 
uncouples mitochondrial fission and apoptosis. Mol Cell. 
2008;29:409-10.
